Search Results
Search for other papers by Francesco Boi in
Google Scholar
PubMed
Search for other papers by Fabiana Pani in
Google Scholar
PubMed
Search for other papers by Stefano Mariotti in
Google Scholar
PubMed
case of papillary thyroid carcinoma associated with diffuse lymphocytic thyroid infiltration. Also, in several clinical studies (detailed in the next paragraphs), a significant association between HT and differentiated thyroid carcinoma
Search for other papers by Laura Ximena Kattah Martinez in
Google Scholar
PubMed
Search for other papers by Lisseth Fernanda Marín Carrillo in
Google Scholar
PubMed
Search for other papers by Leonardo Rojas Melo in
Google Scholar
PubMed
date, this is the first case report of sorafenib-induced acute pancreatitis during the treatment of DTC in progression. Patient A 60-year-old Latin woman with papillary thyroid carcinoma, T4bN1bM1 (ATA classification) attended our practice. She
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Lars Folkestad in
Google Scholar
PubMed
Search for other papers by Frans Brandt in
Google Scholar
PubMed
Search for other papers by Thomas Brix in
Google Scholar
PubMed
Search for other papers by Marianne Vogsen in
Google Scholar
PubMed
Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Search for other papers by Peter Grupe in
Google Scholar
PubMed
Search for other papers by Jeanette Krogh Petersen in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
). Whereas cytokeratin 20, caudal type homeobox 2 (CDX2), and prostate specific antigen (PSA) were negative. It was concluded that the biopsy represented metastatic well-differentiated thyroid carcinoma. Table 1. Key laboratory results The
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Min Ren in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Qianlan Yao in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Longlong Bao in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Zhiting Wang in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Ran Wei in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Qianming Bai in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Bo Ping in
Google Scholar
PubMed
Department of Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, China
Search for other papers by Cai Chang in
Google Scholar
PubMed
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Search for other papers by Yu Wang in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Xiaoyan Zhou in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Search for other papers by Xiaoli Zhu in
Google Scholar
PubMed
of uncertain malignant potential; MTC, medullary thyroid carcinoma; PTC, papillary thyroid carcinoma. In the cohort of 193 PTCs, 181 samples (93.8%) had pathological/likely pathological mutations by NGS testing. BRAF was the most commonly
Center for Health Technology and Services Research (CINTESIS), Porto, Portugal
Search for other papers by Claudia Matta-Coelho in
Google Scholar
PubMed
Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed
Search for other papers by Helena Vilar in
Google Scholar
PubMed
Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
-Tg antibodies, and BM detected by the whole-body scan at the time of RAIT. The other patient with a papillary thyroid carcinoma (PTC) had strongly positive anti-Tg antibodies during follow-up, and BM were detected preoperatively by CT performed for staging
Search for other papers by Gilles Russ in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
, Chang KH, Sohn CH, Choi YH: Sonographic features of follicular variant papillary thyroid carcinomas in comparison with conventional papillary thyroid carcinomas. J Ultrasound Med 2009;28:1685-1692. 19933483 36 Kim DW, Jung SJ, Eom JW, Kang T
Search for other papers by Lucie Allard in
Google Scholar
PubMed
Search for other papers by Jérôme Alexandre Denis in
Google Scholar
PubMed
Search for other papers by Gaëlle Godiris Petit in
Google Scholar
PubMed
Search for other papers by Gabrielle Deniziaut in
Google Scholar
PubMed
Search for other papers by Cécile Ghander in
Google Scholar
PubMed
Search for other papers by Elise Mathy in
Google Scholar
PubMed
Search for other papers by Erell Guillerm in
Google Scholar
PubMed
Search for other papers by Charlotte Lussey-Lepoutre in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
Search for other papers by Camille Buffet in
Google Scholar
PubMed
compressive symptoms. The patient had refused surgery on a 6 cm-papillary thyroid carcinoma (PTC) diagnosed 3 years earlier. Initially, considering the size of the tumor, anaplastic or at least poorly differentiated carcinoma was suspected. Unexpectedly, but
Search for other papers by Emilio Fiore in
Google Scholar
PubMed
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Introduction This review will focus on two different, related topics: (a) iodine and thyroid autoimmunity and (b) thyroid autoimmunity and papillary thyroid carcinoma (PTC). We will review the latest data on these issues and describe our more
Diabetes and Metabolism Research Unit, Vall Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Barcelona, Spain
Search for other papers by Carles Zafon in
Google Scholar
PubMed
Search for other papers by Juan Antonio Baena in
Google Scholar
PubMed
Search for other papers by Josep Castellví in
Google Scholar
PubMed
Diabetes and Metabolism Research Unit, Vall Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Barcelona, Spain
Search for other papers by Gabriel Obiols in
Google Scholar
PubMed
Search for other papers by Oscar Gonzalez in
Google Scholar
PubMed
Search for other papers by José Manuel Fort in
Google Scholar
PubMed
Search for other papers by Ramon Vilallonga in
Google Scholar
PubMed
Search for other papers by Enric Caubet in
Google Scholar
PubMed
Search for other papers by Manuel Armengol in
Google Scholar
PubMed
Diabetes and Metabolism Research Unit, Vall Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Barcelona, Spain
Search for other papers by Jordi Mesa in
Google Scholar
PubMed
Introduction Numerous studies have shown a worldwide increase in the incidence of thyroid cancer (TC) in recent years [ 1 ] due to the increased frequency of papillary thyroid carcinoma (PTC). The reason for this increase is not well
Search for other papers by Helmi Khadra in
Google Scholar
PubMed
Search for other papers by Ahmed Deniwar in
Google Scholar
PubMed
Search for other papers by Khuzema Mohsin in
Google Scholar
PubMed
Search for other papers by Dominique Monlezun in
Google Scholar
PubMed
Search for other papers by Emad Kandil in
Google Scholar
PubMed
, Zhu Z, et al: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454–1457. 8 Xing M: BRAF mutation in